Skip to Main Content
Contribute Try STAT+ Today

Among the myriad changes wrought by the Covid-19 pandemic, Food and Drug Administration advisory committee meetings to review medicines are “rarer and tougher” now, according to one Wall Street analyst.

Over the past year, just half of new drug applications taken to advisory committees were recommended for regulatory approval. That compares with 78% in 2019 and a rate of more than 80% in three of the four years before that, according to Cowen analyst Rick Weissenstein, who cited an analysis by the Prevision Policy consulting firm in an investor note.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Seems logical to me. Consider the ones that would have gone to Panel during a normal year. The ones highly likely to be approved didn’t go to panel in 2020, FDA didn’t bother and approved without AdCom. Hence the overall number dropped, and also the success rate dropped.

    Since, logically, the likely winners were the ones (correctly) that went straight to approval.

Comments are closed.